Gilead to launch ‘Zydelig Tab’ in the domestic market

Gilead Sciences has acquired a domestic sales approval for Zydelig(generic name: idealisib), a lymphocytic leukemia treatment.

The Ministry of Food and Drug Safety approved sales of Zydelig Tab 100mg and 150mg, a B-cell non-Hodgkin lymphomas treatment.

Zydelig is an anticancer drug which inhibits ‘PI3K,’ a type of protein overexpressed in B-cell malignant tumor and related to survival, prolif...